GeneVentiv Welcomes New Advisors

August 29, 2023

Damon R. Race, President & CEO

RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced that it has added Robert Baffi and Deborah Wild as Advisors as the Company prepares to manufacture AAV8.FVa for studies leading into an Investigational New Drug (IND) application.

“We are extremely proud to welcome Robert and Deborah as advisors to the Company.  Both leaders bring a wealth of business and gene therapy manufacturing experience,” commented Damon Race, CEO of GeneVentiv Therapeutics.  Robert Baffi most recently served as President of Global Manufacturing and Technical Operations at BioMarin with the capstone achievement of pioneering and establishing the high-yield gene therapy manufacturing process for RoctavianTM, a hemophilia A gene therapy.   Deborah Wild has held CEO and leadership roles in multiple contract development and manufacturing organizations, bringing over 30 years of cell and gene manufacturing experience.

Robert Baffi brings more than 30 years of biologics manufacturing experience, including pioneering and establishing innovative methods for large-scale, high-yielding gene therapy production. During a 23-year tenure at BioMarin Pharmaceutical Inc. and as President of Global Manufacturing & Technical Operations he was responsible for overseeing manufacturing, process development, quality, logistics, engineering, and analytical chemistry. Dr. Baffi served 14 years at Genentech, Inc., primarily in the functional area of quality control. Prior to Genentech, Dr. Baffi worked for Cooper BioMedical as a Research Scientist and at the Becton Dickinson Research Center as a Post-Doctoral Fellow. Dr. Baffi has contributed to the approval and commercial success of 30 products and a dozen patents covering diverse technologies. He serves on the board of Neurogene Inc., Bionic Sight and Mosaic ImmunoEngineering and is a venture partner with Samsara BioCapital. Dr. Baffi received a Ph.D., M. Phil., and a B.S. in biochemistry from the City University of New York and an M.B.A. from Regis University.

Deborah Wild is an accomplished C-Suite BioPharma Executive with 30+ years’ experience leading large groups including manufacturing, supply-chain, quality assurance, quality control, validation, regulatory affairs and client and business management. She has earned a strong reputation for leading high growth and effective turnarounds by transforming organizations and equipping them with strong business leaders and partners.

Deb’s prior roles include Chief Executive Officer at Cellipont Bioservices, Chief Quality and Regulatory Affairs Officer, Chief of Staff and Client Business Management at Paragon BioServices/Catalent Gene Therapy where she was part of executive leadership team that led to the successful sale of the business to Catalent. Prior to this, she was VP of Quality Systems at Polynoma and VP of Manufacturing and Supply Chain at Victory Pharma. She also spent 17 years at Genentech in various leadership roles in Manufacturing Operations, Supply Chain and Quality.  Deborah was deployed during Desert Storm and is a US Army Veteran and is a graduate of Austin Peay State University.

About GeneVentiv Therapeutics:

GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on blood diseases and disorders.  Our lead program, GENV-HEM, is the first universal gene therapy treatment for Hemophilia A and B with or without inhibitors.  GENV-HEM has received Orphan Drug Designation from the FDA and a Letter of Support from the National Hemophilia Foundation.   GeneVentiv is advancing an additional gene therapy for Hemophilia Arthropathy, a degenerative joint disease afflicting roughly 50% of patients with hemophilia.